SK Capital Completes Strategic Investment in Ecopol
14.9.2023 07:30:00 EEST | Business Wire | Press release
Ecopol S.p.A. (“Ecopol” or the “Company”), a leading developer and producer of innovative biodegradable films and delivery systems, announced today the completion of a strategic investment from affiliates of SK Capital Partners, LP (“SK Capital”), a leading private investment firm focused on the specialty materials, ingredients, and life sciences sectors. SK Capital has acquired a majority interest in the Company with Mauro Carbone, Ecopol’s CEO and controlling shareholder, retaining a significant stake and remaining as both the CEO and largest individual shareholder. It is also announced the formation of a new Board of Directors, which includes industry leaders with extensive experience across sustainable materials and consumer packaged goods (“CPG”) markets in Ecopol’s value chains, including Jan-Dirk Auris, E. Craig Mitchell, Daniele Ferrari and Dave Mezzanotte.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230913054522/en/
“Ecopol is pleased to begin our partnership with SK Capital and to be working with a diverse team of high-impact industry executives who have joined our Board of Directors,” said Mauro Carbone, Ecopol CEO. “I am excited for the next chapter of our journey as we work together to accelerate Ecopol’s rapid growth and continue to make strategic investments to provide even greater value for our global customer base and bring more sustainable solutions to both existing and new markets. We are grateful to Roberto Quagliuolo, Luca Bucelli and Laurent Labatut for their contributions as former Board Directors and look forward to Tikehau Capital’s continued support as an ongoing minority shareholder.”
“In partnership with Mauro, we have assembled a world-class Board of Directors who will be highly impactful in helping Ecopol execute its strategic priorities and achieve its vision to become the global leader in highly innovative and sustainable delivery systems,” added Stephen D’Incelli, Managing Director at SK Capital. “We look forward as a Board to supporting Mauro and his leadership team in driving Ecopol’s next phase of transformational growth.”
In connection with the closing, SK Capital and Mauro have appointed the following Board Directors:
Jan-Dirk Auris spent over 35 years at Henkel AG & Co. KGaA (“Henkel”), where he served in a variety of senior executive roles and as a member of the Henkel Management Board. He most recently led Henkel’s Adhesives Technologies business unit, where he had extensive experience serving leading global CPG companies. Mr. Auris played a leading role in implementing a new performance management playbook across Henkel and driving innovation and sustainability initiatives.
E. Craig Mitchell has over 35 years of experience in the specialty materials industry and currently serves as President, Flavors and Extracts Group at Sensient Technologies Corporation. He previously served in critical roles at global leaders in Ecopol’s supply chain, including President and COO of Sekisui Specialty Chemicals America, LLC, a manufacturer of polyvinyl alcohol, as well as VP of Sales, Americas of Celanese Corporation, a producer of vinyl acetate monomer.
Daniele Ferrari will serve as Board Chairman. Mr. Ferrari, who is based full-time in Italy, has over 35 years of experience in the specialty materials industry, most recently as the CEO of Versalis S.p.A., the largest chemical company in Italy, and as Chairman of Matrìca S.p.A., a joint-venture with Novamont, a leader in the bio-plastics industry at the forefront of renewable chemistry. Mr. Ferrari has served as a Senior Director at SK Capital and brings significant sustainability leadership in prior roles as President of the European Chemical Industry Council (“CEFIC”), President of Plastics Europe, and as a board member of the Alliance to End Plastics Waste.
Dave Mezzanotte has over 40 years of experience in the specialty materials and packaging industries and has served as a Senior Director at SK Capital since 2018. He previously was Chairman and CEO of Coveris, a global manufacturer of flexible consumer packaging, and CEO of CHEP, a global logistics services provider for CPGs.
The Board of Directors also includes Mauro Carbone, Ecopol CEO and significant minority investor; Stephen d’Incelli, Deal Lead and Managing Director at SK Capital; and Josh Lieberman, Principal at SK Capital.
Latham & Watkins LLP served as legal counsel to SK Capital. Lead arrangers and bookrunners Crédit Agricole Italia S.p.A. and Intesa Sanpaolo S.p.A provided committed financing in support of the transaction. Legance and Alpeggiani Studio Legale Associato served as legal counsel and STS Deloitte served as tax advisor to Ecopol. UBS served as financial advisor.
About Ecopol
Ecopol is a leading global producer of water-soluble and biodegradable films. The Company’s innovative delivery systems for unit-dose applications allow the world’s leading brands to significantly reduce CO2 emissions and the usage of water and virgin plastic throughout their supply chains. Headquartered in Chiesina Uzzanese, Tuscany, Ecopol operates production campuses in Italy and the United States, providing the highest levels of service, technical support and innovation partnership to its worldwide customer base. For more information, please visit www.ecopol.com.
About SK Capital
SK Capital is a private investment firm with a disciplined focus on the specialty materials, ingredients and life sciences sectors. The firm seeks to build resilient, sustainable and growing businesses that create substantial long-term economic value. SK Capital aims to utilize its industry, operating and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth and profitability, as well as lower operating risk. SK Capital’s portfolio of businesses generates revenues of approximately $17 billion annually, employs more than 25,000 people globally, and operates more than 200 plants in over 30 countries. The firm currently has approximately $7.8 billion in assets under management. For more information, please visit www.skcapitalpartners.com.
About Tikehau Capital
Tikehau Capital is a global alternative asset management group with €41.1 billion of assets under management (as of 30 June 2023). Tikehau Capital has developed a wide range of expertise across four asset classes (private debt, real assets, private equity and capital markets strategies) as well as multi-asset and special opportunities strategies. Leveraging its strong equity base (€3.1 billion of shareholders’ equity as of 30 June 2023), the firm invests its own capital alongside its investor-clients within each of its strategies. Controlled by its managers alongside leading institutional partners, Tikehau Capital is guided by a strong entrepreneurial spirit and DNA, shared by its 742 employees (as of 30 June 2023) across its 15 offices in Europe, the Middle East, Asia and North America. Tikehau Capital is listed in compartment A of the regulated Euronext Paris market (ISIN code: FR0013230612; Ticker: TKO.FP). For more information, please visit www.tikehaucapital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913054522/en/
Contact information
Jeremy Milner
BackBay Communications
jeremy.milner@backbaycommunications.com
(401) 862-9422
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
